Schrödinger Cans Early-Stage Blood Cancer Drug After Two Patient Deaths
After two patients who received the investigational CDC7 blocker died, pushing forward with SGR-2921’s development would be “difficult,” according to Schrödinger, whose stock dropped 17.5% before the opening bell on Thursday.Read more:
biospace.comBiotechnology